Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Advanced Heart Failure and Transplant
In patients with resolved LV thrombus post-MI after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
If so, how often would you do this?
Related Questions
What patient characteristics prompt you to prescribe vericiguat for patients with heart failure with reduced ejection fraction who are already on standard therapy?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Are there any circumstances in which you would consider PCI for CAV, especially for focal/tubular lesions, if the patient is a candidate for re-transplantation?
Does the presence of diastolic dysfunction guide subsequent pharmacological, pacing and ablative therapies for atrial fibrillation?
Do you routinely check digoxin levels, and if so, when would you consider using Digibind in chronic digoxin use patients?
How do you decide when to refer patients with obstructive hypertrophic cardiomyopathy for alcohol septal ablation versus septal myectomy?
When would you consider using hypertonic saline for patients with refractory acute decompensated heart failure and diuretic resistance?
Should there be a role for sacubitril-valsartan in the management of patients with heart failure with preserved ejection fraction?
For patients with HF with recovered LVEF, would it be reasonable to begin considering GLP1 RAs, finerenone for them in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?
When would be your threshold to consider obtaining an exercise RHC for undifferentiated dyspnea to help diagnose HFpEF?